In Africa, malaria remains one of the leading causes of death in young children. Every minute, a child dies from the disease—most of them under the age of five.
But a new medicine developed specifically for babies could be a turning point. It’s called Coartem Baby—the first malaria drug in the world tailored for infants. It’s just been approved in Ghana and could be rolled out by the end of the year.
But just as science is making progress, international funding for malaria prevention and research is in decline. Major cuts to U.S. foreign aid—particularly under the current Trump administration have left critical gaps in prevention efforts, drug development, and mosquito control programs. This project investigates how these cuts are affecting frontline malaria research, including gene drive experiments and vector control studies in Ghana.
